Scrip Asks… Inside 2026: The Forces, Decisions and Challenges Redefining Biopharma
Scrip gathered predictions from a record 300-plus pharma executives, biotech leaders, investors and industry experts on the trends set to shape 2026.
From M&A and global competition to pricing, R&D advances and operational transformation through AI, their insights are collected across our five-part Scrip Asks series.
Complete the form to read more.
See where biopharma funding is really flowing in 2026
Get a clear picture of how financing conditions are changing. Find out what’s coming back, what's still constrained, and which assets investors are backing.
Benchmark your strategy against industry leaders and active deal‑makers
Use our data‑driven analysis and league‑table insights to compare your financing, growth, and valuation projections against other biopharma and medtech.
Understand how financing connects to M&A, innovation, and long‑term growth
Go beyond the headlines to see how capital allocation links to patent risk, deal‑making, and innovation strategies.
